Moderna and Merck's Cancer Vaccine Shows Promising Results in Reducing Metastases.
TL;DR Summary
Moderna and Merck's personalized cancer vaccine, made from mRNA-encoding molecular mugshots unique to an individual's tumor, significantly reduced the risk of developing deadly metastases by 65% in patients who underwent surgery to remove high-risk skin cancer, when combined with Merck's immunotherapy Keytruda, compared to patients taking Keytruda alone.
- Moderna, Merck say their cancer vaccine reduces metastases by 65% in PhII study of high-risk melanoma: #ASCO23 Endpoints News
- Moderna and Merck cancer vaccine used with Keytruda reduces risk of deadly skin cancer spreading CNBC
- Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data Yahoo News
- Moderna and Merck reveal new data on individualized cancer treatment MarketWatch
Reading Insights
Total Reads
0
Unique Readers
9
Time Saved
0 min
vs 1 min read
Condensed
58%
114 → 48 words
Want the full story? Read the original article
Read on Endpoints News